SPARKS, NV / ACCESSWIRE / April 25, 2023 / Ludwig Enterprises, Inc., OTC:LUDG (Ludwig - The Genomics Language Company) has released its strategic sales and marketing plan as it launches its ground-breaking nutraceutical, NuGenea™. NuGenea, which means ‘New Life" in Greek, is a nutraceutical created by a physician and formulated with 20 different ingredients which have been scientifically shown to help fight chronic inflammation.

"Chronic inflammation is a causative factor in illnesses such as cancer, diabetes, COPD and heart disease," said Dr. Marvin S. Hausman MD, NuGenea's creator. "The World Health Organization estimates that more than 50% of the world's deaths result from these illnesses. We believe NuGenea has the potential to improve the health of a large number of people."

"Ludwig's primary sales and marketing strategies for NuGenea will include Direct to Consumer and Direct to Healthcare Professionals," said Luke Fannon, Chief Marketing Officer. "The company's new ecommerce website will debut shortly, and consumers will be able to purchase the product directly. We are very excited to offer discounts for volume purchases and monthly product memberships."

NuGenea's direct to consumer strategy will include digital and traditional advertising, content and native marketing and placement in retail locations.

Integrative Medicine Professionals, which includes physicians, chiropractors, naturopathic physicians, and wellness clinics, will be a major focus for Ludwig's sales and marketing team according to Fannon. "This fast-growing branch of professionals believes in a holistic approach to their patient's care which includes lifestyle and diet changes, improvements in diets and usage of nutraceuticals," added Mr. Fannon.

Consumers interested in placing an advanced order for NuGenea can send an email toNuGenea@ludg.us and request to be the first to receive this product. Healthcare professionals who want to discuss wholesale purchases of the product can call NuGenea's product launch department at 484-429-5846.

About Ludwig Enterprises, Inc.

Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics, and nutraceuticals. Through its subsidiary Precision Genomics, it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc and its My RNA for Life™ product line of nutraceuticals.

Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia, and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig's innovative testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiaries Precision Genomics, Inc and mRNAforLife, Inc. are poised to significantly impact how we think about disease and live longer healthier lives. For more information please visit: http://www.ludwigent.com.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Ludwig Enterprises, Inc.

For Scientific Related Inquiries
Dr. Marvin S. Hausman MD Chief Science Officer
503-327-4173

For Business Related Inquiries
Luke J. Fannon
484-429-5846
www.ludwigent.com

SOURCE: Ludwig Enterprises, Inc.